Ritholtz Wealth Management Decreases Stake in Takeda Pharmaceutical Co. (NYSE:TAK)

Ritholtz Wealth Management reduced its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 7.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,247 shares of the company’s stock after selling 1,982 shares during the period. Ritholtz Wealth Management’s holdings in Takeda Pharmaceutical were worth $346,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its position in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after buying an additional 2,411 shares during the last quarter. Simon Quick Advisors LLC purchased a new position in Takeda Pharmaceutical in the 1st quarter valued at about $164,000. GAMMA Investing LLC boosted its position in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after buying an additional 1,296 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after buying an additional 1,045 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its position in Takeda Pharmaceutical by 15.1% in the 1st quarter. Park Avenue Securities LLC now owns 31,828 shares of the company’s stock valued at $473,000 after buying an additional 4,177 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.91 on Friday. The firm has a market cap of $47.43 billion, a PE ratio of 67.75 and a beta of 0.23. The firm’s 50-day simple moving average is $14.77 and its 200-day simple moving average is $14.20. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. Takeda Pharmaceutical Co. has a 1 year low of $12.58 and a 1 year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). The company had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.